Climate change that is happening all around the world and is global that way poses a great threat to the productivity of agriculture and therefore the need for both resilient crops and sustainable farming systems is very strong. Climate-resilient biotechnology has become a major field that is dealing with this issue through the use of the most advanced genetic, microbial, and molecular tools. The present study is a scientometric one and it makes use of data from the Scopus database consisting of 122 scientific publications to map the research field, find the main trends and specify the intellectual structure of this area from 2013 to 2026. The research shows the existence of a very fast-growing field where the main focus of the research is on genome editing especially CRISPR-Cas9 for introducing tolerance to abiotic and biotic stress, the use of plant-growth-promoting microbes for the purpose of improving the plant's resilience, and the combination of omics for trait discovery. The major research areas are: the staples such as wheat, rice and maize, the underutilized nature-resilient crops, and the coming together of biotechnology with AI (artificial intelligence) and models of sustainable systems. The results of the study give evidence of a change in paradigm moving towards precision breeding and biological control measures, and this change is accompanied by the highlighting of the role of biotechnology as critical in securing future food supply under the conditions of volatile climate.

This scientific analysis of 18,441 solid-state battery articles in the Scopus database gives us a picture not only of the whole global research but also of the most dynamic parts of it. The issue leads to a conclusion that the Chinese researchers are the ones that produce the most papers, which is an expression of the Chinese government's great attention to energy innovation. It is also noteworthy that the two major Chinese governmental funding organizations support more than half of the research, which is an indication of the strong institutional commitment to the development of battery technologies. The distribution of disciplines shows a strong interdisciplinary base, with Material Science, Chemistry, Energy, and Engineering being the main contributors. These areas are working together to make breakthroughs in solid electrolytes, interface stability, and scalable manufacturing. The analysis points out that the solid-state battery research is not only technically involved but also geopolitically focused, with China as the key player in determining the direction and influence of the research. This research presents an all-encompassing picture of the intellectual and institutional map, giving clues to the main themes and funding trends that are crucial for the progress of the future energy storage systems.

The worldwide prevalence of type 2 diabetes (T2D) and obesity has been a driving force behind the heavy research on glucagon-like peptide-1 receptor agonists (GLP-1RAs). Orforglipron, an innovative, oral, non-peptide GLP-1RA, is a major development in the therapeutic field, and it has the potential to make the delivery of drugs easier and more patient-friendly than the usual injections. The purpose of this scientometric study is to present the scientific works on orforglipron and thus portray its research landscape, important topics, and growing evidence base. A detailed examination of 101 scientific works (from 2023 to 2025) taken from the Scopus database has been done in this study. The documents were divided into categories depending on the type (e.g., clinical trial, review, meta-analysis), the theme dealt with, and the writer's background. The synthesis included research trends in focus, drug efficacy and safety outcomes, and positioning of the drug within the larger area of pharmacotherapy. The literature on orforglipron has just begun, with the first publications coming out in 2023. The data set consists of a substantial primary research foundation comprising clinical trials of all three Phases, plus a great number of reviews, meta-analyses, and editorial commentaries. The major research themes are: (1) Efficacy in Type 2 Diabetes and obesity, showing pronounced drops in HbA1c and body weight; (2) Safety and tolerability, where the main concern is with gastrointestinal adverse events; (3) Comparative effectiveness against other GLP-1RAs and multi-agonists; (4) Pharmacological characterization as a small-molecule agonist; and (5) The potential role of the drug in cardiovascular risk reduction and other areas that are yet to be explored. The scientific literature surrounding orforglipron is growing at a rapid pace and this indicates that there is a high interest in the drug's potential to change the management of T2D and obesity. The current evidence places it as a powerful, oral option to be administered instead of GLP-1RAs that are delivered by injection. The future research initiatives will probably be directed towards the investigation of the long-term cardiovascular outcomes, real-world effectiveness, and the use in a broader range of patients with different diseases.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), originally designed for the management of type 2 diabetes (T2DM) and weight loss, have turned out to be a potential therapeutic target for neurodegenerative diseases. The present scientometrics study carries out a detailed analysis of 119 scienctific studies to the front of publications in the Scopus database (2011-2026) and maps the academic structure, thematic development, and main research areas in this rapidly growing field. The examination points out a strong increase in the number of publications, particularly from 2022 onward, which marks a major paradigm shift in considering GLP-1 RAs as possible neuroprotectors. Among the main research areas are: (1) Mechanistic Preclinical Studies, which account for the majority of publications and explain insulin signaling, neuroinflammation, oxidative stress, apoptosis and synaptic plasticity through the different pathways; (2) Clinical and Real-World Evidence, comprising of retrospective cohort studies and the first randomized controlled trials (RCTs) that show a decrease in dementia and Parkinson's disease (PD) among T2DM patients; (3) Drug-Specific Investigations, that discuss the effects of liraglutide, semaglutide, exendin-4, and the dual agonist tirzepatide; and (4) Disease-Specific Applications, primarily concentrating on Alzheimer's disease (AD) and PD. The field is characterized by a powerful shift from animal models to human trials and is starting to test applications in other areas besides the classic neurodegeneration such as cognitive dysfunction in obesity, psychiatric disorders and other CNS conditions. This survey encapsulates the present knowledge, puts the limelight on the contributions of pivotal Ais and research groups, and points out the future directions for this very promising area of therapeutic development.

Semaglutide, which is a glucagon-like peptide-1 receptor agonist (GLP-1 RA), has shown significant effects for weight loss in RCTs. However, good results obtained during clinical trials are not necessarily reflected in everyday practice because of factors such as adherence, dosing, patient differences, and healthcare system limitations. In this review, we present the results of 67 studies as real-world evidence (RWE) that help to assess semaglutide's effectiveness in weight control. RWE gives a constant message that semaglutide does indeed cause weight loss that is clinically significant in varieties of patients including those with type 2 diabetes (T2D) and simply obesity. Although the reduction in weight in real clinical situations is generally somewhat less than in RCTs, the studies speak of weight losses of 4-6% over 6-7 months and 9-15% over 12 months, with even greater losses among the most compliant patients. Some of the main barriers are identified as high dropout rates, inadequate dose titration, and the effects of both access and cost. Nevertheless, semaglutide proves to be a very effective option in standard care, with its positive effects on glycemic control, cardiovascular risk factors, and patient-reported outcomes. This paper highlights the importance of RWE in confirming, and sometimes even augmenting, RCT outcomes, as well as in providing support for clinical decision making in weight loss therapy.